Rep. Josh Gottheimer Acquires Genmab A/S (NASDAQ:GMAB) Stock

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Genmab A/S (NASDAQ:GMAB). In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Genmab A/S stock on January 16th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Genmab A/S Stock Performance

Shares of GMAB opened at $18.89 on Wednesday. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The stock has a market capitalization of $12.50 billion, a price-to-earnings ratio of 18.34, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. The stock’s 50-day simple moving average is $20.78 and its 200 day simple moving average is $23.30.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Advisers LP increased its position in Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares during the last quarter. ABC Arbitrage SA acquired a new stake in Genmab A/S during the fourth quarter worth about $3,692,000. AIMZ Investment Advisors LLC acquired a new position in shares of Genmab A/S in the fourth quarter valued at $3,525,000. Raymond James Financial Inc. bought a new position in shares of Genmab A/S during the 4th quarter worth about $2,463,000. Finally, Y Intercept Hong Kong Ltd boosted its holdings in Genmab A/S by 371.0% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock valued at $1,538,000 after purchasing an additional 58,048 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on GMAB shares. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average price target of $45.20.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.